Patients who take capecitabine after surgery for bile duct cancer live for almost a year and a half longer than those not given the drug, according to the results of a Cancer Research UK funded trial presented at the 2017 ...
May 18, 2017
0
152
Rectal cancer patients who use a new combination of the chemotherapy, Capecitabine, together with five weeks of radiation (50 Gy) before surgery have an 88 percent chance of surviving the cancer three years after treatment, ...
Sep 26, 2011
0
0
Among patients with previously treated HER2-positive metastatic breast cancer, those who received pyrotinib plus capecitabine had longer overall survival than those who received lapatinib (Tykerb) plus capecitabine, according ...
Dec 8, 2021
0
2
(HealthDay)—Secondary prophylaxis with diltiazem may offer cancer patients relief from capecitabine-induced chest pain and dyspnea and allow them to tolerate capecitabine treatment, according to a study published in the ...
Nov 16, 2012
0
0
(HealthDay)—Guidelines relating to the appropriate adjuvant regimen for patients with pancreatic cancer have been updated in light of new evidence, according to a special article published online April 11 in the Journal ...
Apr 17, 2017
0
2
The sizeable and increasing proportion of women with advanced breast cancer whose disease has spread to the brain could be effectively treated systemically with a combination of two drugs, sparing them the debilitating neurological ...
Nov 1, 2012
0
0
Something as seemingly harmless as a heartburn pill could lead cancer patients to take a turn for the worse. A University of Alberta study published in journal JAMA Oncology discovered that proton pump inhibitors (PPIs), ...
Dec 16, 2016
0
2
For women with metastatic, HER2-positive breast cancer, the amount of HER2 on their tumor might determine how much they benefit from a drug called trastuzumab emtansine (T-DM1), according to data from a subanalysis of the ...
Apr 7, 2013
0
0
Locally advanced rectal cancer patients who receive preoperative radiation therapy with either irinotecan plus capecitabine or oxaliplatin plus capecitabine have a four-year overall survival rate of 85 percent and 75 percent, ...
Jan 9, 2015
0
10
(HealthDay)—Capecitabine (Xeloda) can extend the lives of patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have residual invasive disease after receipt of neoadjuvant chemotherapy, ...
Jun 1, 2017
0
1
Capecitabine (INN) ( /keɪpˈsaɪtəbiːn/) (Xeloda, Roche) is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.[citation needed] The activation of capecitabine follows a pathway with three enzymatic steps and two intermediary metabolites, 5'-deoxy-5-fluorocytidine (5'-DFCR) and 5'-deoxy-5-fluorouridine (5'-DFUR), to form 5-fluorouracil.[citation needed]
This text uses material from Wikipedia, licensed under CC BY-SA
